Date: 2012-03-28
Type of information: R&D agreement
Compound: use of BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono
Company: Merck Serono (Germany) Bioseek (USA)
Therapeutic area: Multiple therapeutic areas
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: BioSeek, a subsidiary of Asterand plc (LSE: ATD), a pioneer in the application of predictive human biology to drug discovery, has signed a new, three-year collaboration agreement with Merck Serono, a division of Merck KGaA, Darmstadt, Germany.
The new agreement extends and expands the companies’ previous three-year agreement from 2009. Under the new research plan, BioSeek will expand the use of its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection and optimization and nomination of candidates for preclinical development at Merck Serono.
BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database. Assessment with BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on-and off-target effects, dose responses, and the discrimination of closely related compounds.
Financial terms:
Latest news:
